Using oxytocin to improve memory and cognitive function in individuals with Fragile X syndrome
Postnatal Oxytocin Treatment and Cognitive Function in Fragile X
['FUNDING_R01'] · UNIVERSITY OF CALIFORNIA-IRVINE · NIH-11065492
This study is looking at how a treatment with oxytocin, a hormone, might help improve memory and learning in people with Fragile X syndrome, which is often linked to autism, by testing it on mice during their early development.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA-IRVINE (nih funded) |
| Locations | 1 site (IRVINE, UNITED STATES) |
| Trial ID | NIH-11065492 on ClinicalTrials.gov |
What this research studies
This research investigates the effects of postnatal oxytocin treatment on cognitive function, particularly episodic memory, in individuals with Fragile X syndrome, a condition often associated with Autism Spectrum Disorder. The study utilizes a mouse model to explore how oxytocin can enhance learning and memory capabilities by targeting brain maturation during critical developmental periods. By administering intranasal oxytocin during early postnatal weeks, researchers aim to assess improvements in memory and social recognition in adulthood. The findings could provide insights into potential therapeutic strategies for enhancing cognitive function in affected individuals.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Fragile X syndrome or Autism Spectrum Disorder, particularly those experiencing cognitive difficulties.
Not a fit: Patients without a diagnosis of Fragile X syndrome or Autism Spectrum Disorder may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve cognitive function and social interactions in individuals with Fragile X syndrome and related conditions.
How similar studies have performed: Previous studies have shown promising results with oxytocin treatment in improving social behaviors in autistic individuals, suggesting potential for success in this novel application.
Where this research is happening
IRVINE, UNITED STATES
- UNIVERSITY OF CALIFORNIA-IRVINE — IRVINE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GALL, CHRISTINE M — UNIVERSITY OF CALIFORNIA-IRVINE
- Study coordinator: GALL, CHRISTINE M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.